Cell Signaling – News and Features

A study from the University of the Basque Country explores blood-based biomarkers to understand why some cannabis users develop schizophrenia. Using lipidomics, researchers identified specific fatty acid profiles that differentiated users.

A study from St. Jude Children’s Research Hospital reveals that the protein VDAC2 acts as a “signal jammer” in tumors, preventing immune system communication. By removing VDAC2, tumors became more sensitive to immunotherapy.

Researchers find that tumor stem cells became less able to proliferate and invade tissues when gene editing blocked the production of the prion protein; the results suggest that the molecule could be a therapeutic target.

Researchers have identified novel mechanisms regulating the development of the spinal column, which could inform new treatments for congenital scoliosis and other related birth defects.

Pancreatic cancer has a notorious capacity to adapt and resist therapy. Now, a study uncovers a hidden driver of this adaptability: extrachromosomal DNA (ecDNA).

Technology Networks caught up with Professor Mazhar Adli to learn more about his research on the characterization of essential human genes and the benefits of using inducible degrons to study gene function.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.

Scientists at St. Jude Children’s Research Hospital have used positron emission tomography (PET) with edaravone, a drug used to treat ALS, to detect oxidative stress, which leads to brain damage.

A discovery in cardiac regeneration offers ew hope for the treatment of ischemic heart failure. Published in npj Regenerative Medicine, the study reveals a novel approach to promoting cardiomyocyte proliferation.

Researchers at Washington University and Stanford developed a cannabinoid compound that provides pain relief without psychoactive effects. By targeting a hidden pocket in the CB1 receptor, the drug avoids addiction risks.